DSP-5336 + [14C]-DSP-5336
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Hematologic Malignancies
Conditions
Advanced Hematologic Malignancies
Trial Timeline
Mar 2, 2026 → Aug 1, 2026
NCT ID
NCT07444268About DSP-5336 + [14C]-DSP-5336
DSP-5336 + [14C]-DSP-5336 is a phase 1 stage product being developed by Sumitomo Pharma for Advanced Hematologic Malignancies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07444268. Target conditions include Advanced Hematologic Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07444268 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Hematologic Malignancies